Small-molecule inhibitors of the Rce1p CaaX protease

Journal of Biomolecular Screening

Volumn 12, Issue 7, 2007, Pages 983-993

  Manandhar, Surya P ^a   Hildebrandt, Emily R ^a   Schmidt, Walter K ^a  

^a University of Georgia ^*  (United States)

Author keywords

CaaX protein; Isoprenylation; Posttranslational modification; Protease; Ras

Indexed keywords

ENZYME INHIBITOR; PHEROMONE; PROTEIN S ISOPRENYLCYSTEINE O METHYLTRANSFERASE; PROTEINASE; RAS PROTEIN; RCE1P CAAX PROTEIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COLLOID; ENZYME INHIBITION; ENZYME SPECIFICITY; IC 50; ISOPRENYLATION; MOLECULAR LIBRARY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PROCESSING; WILD TYPE; YEAST;

ENDOPEPTIDASES; HYDROLYSIS; LIGHT; PROTEASE INHIBITORS; PROTEIN PRENYLATION; SCATTERING, RADIATION;

EID: 35148833800     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107307226     Document Type: Article

References (50)

1. Young SG, Ambroziak P., Kim E., Clarke S.: Postisoprenylation protein processing: CXXX (CaaX) endoproteases and isoprenylcysteine carboxyl methyltransferase. In Tamanoi F, Sigman DS (eds): The Enzymes. New York: Academic Press, 2001.
2. Winter-Vann AM, Casey PJ: Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 2005 ; 5: 405-412.
3. Boyartchuk VL, Ashby MN, Rine J.: Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science 1997 ; 275: 1796-1800.
4. Tam A., Nouvet F., Fujimura-Kamada K., Slunt H., Sisodia SS, Michaelis S.: Dual roles for Ste24p in yeast a-factor maturation: NH2-terminal proteolysis and COOH-terminal CAAX processing. J Cell Biol 1998 ; 142: 635-649.
5. Trueblood CE, Boyartchuk VL, Picologlou EA, Rozema D., Poulter CD, Rine J.: The CaaX proteases, Afc1p and Rce1p, have overlapping but distinct substrate specificities. Mol Cell Biol 2000 ; 20: 4381-4392.
6. Romano JD, Schmidt WK, Michaelis S.: The Saccharomyces cerevisiae prenylcysteine carboxyl methltransferase Ste14p is in the endoplasmic reticulum membrane. Mol Biol Cell 1998 ; 9: 2231-2247.
7. Schmidt WK, Tam A., Fujimura-Kamada K., Michaelis S.: Endoplasmic reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. Proc Natl Acad Sci U S A 1998 ; 95: 11175-11180.
8. Cox A., Der C.: Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol 2002 ; 2: 388-393.
9. Zhu K., Hamilton AD, Sebti SM: Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs 2003 ; 4: 1428-1435.
10. Dolence EK, Dolence JM, Poulter CD: Solid-phase synthesis of a farnesylated CaaX peptide library: inhibitors of the Ras CaaX endoprotease. J Comb Chem 2000 ; 2: 522-536.
11. Schlitzer M., Winter-Vann A., Casey PJ: Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1. Bioorg Med Chem Lett 2001 ; 11: 425-427.
12. Anderson JL, Henriksen BS, Gibbs RA, Hrycyna CA: The isoprenoid substrate specificity of isoprenylcysteine carboxylmethyltransferase: development of novel inhibitors. J Biol Chem 2005 ; 280: 29454-29461.
13. Winter-Vann AM, Baron RA, Wong W., de la Cruz J., York JD, Gooden DM,, et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A 2005 ; 102: 4336-4341.
14. Agarwal AK, Fryns JP, Auchus RJ, Garg A.: Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet 2003 ; 12: 1995 -2001.
15. Young SG, Fong LG, Michaelis S.: Prelamin A, Zmpste24, misshapen cell nuclei, and progeria-new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res 2005 ; 46: 2531-2558.
16. Farh L., Mitchell D., Deschenes R.: Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modifcation pathway. Arch Biochem Biophys 1995 ; 318: 113-121.
17. Otto JC, Kim E., Young SG, Casey PJ: Cloning and characterization of a mammalian prenyl protein-specific protease. J Biol Chem 1999 ; 274: 8379-8382.
18. Tam A., Schmidt WK, Michaelis S.: The multispanning membrane protein Ste24p catalyzes CAAX proteolysis and NH2-terminal processing of the yeast a-factor precursor. J Biol Chem 2001 ; 276: 46798-46806.
19. Ashby M., King D., Rine J.: Endoproteolytic processing of a farnesylated peptide in vitro. Proc Natl Acad Sci U S A 1992 ; 89: 4613-4617.
20. Dolence JM, Steward LE, Dolence EK, Wong DH, Poulter CD: Studies with recombinant Saccharomyces cerevisiae CaaX prenyl protease Rce1p. Biochemistry 2000 ; 39: 4096-4104.
21. Hollander I., Frommer E., Mallon R.: Human ras-converting enzyme (hRCE1) endoproteolytic activity on K-ras-derived peptides. Anal Biochem 2000 ; 286: 129-137.
22. Holbeck SL: Update on NCI in vitro drug screen utilities. Eur J Cancer 2004 ; 40: 785-793.
23. Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B.,, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem 2001 ; 44: 4042-4049.
24. Rapisarda A., Uranchimeg B., Scudiero DA, Selby M., Sausville EA, Shoemaker RH,, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002 ; 62: 4316-4324.
25. Moloughney JG, D Thomas J., Toney JH: Novel IMP-1 metallo-beta-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1. FEMS Microbiol Lett 2005 ; 243: 65-71.
26. Turkson J., Zhang S., Mora LB, Burns A., Sebti S., Jove R.: A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005 ; 280: 32979-32988.
27. Dorjsuren D., Burnette A., Gray G., Chen X., Zhu W., Roberts P.,, et al. Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis. Antiviral Res 2006 ; 69: 9-23.
28. Chen L., Sung SS, Yip ML, Lawrence HR, Ren Y., Guida WC,, et al. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol 2006 ; 70: 562-570.
29. Marx C., Berger C., Xu F., Amend C., Scott GK, Hann B.,, et al. Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Dev Technol 2006 ; 4: 273-284.
30. Siliciano P., Tatchell K.: Transcription and regulatory signals at the mating type locus in yeast. Cell 1984 ; 37: 969-978.
31. Powers S., Michaelis S., Broek D., Santa Anna S., Field J., Herskowitz I.,, et al. RAM, a gene of yeast required for a functional modification of RAS proteins and for production of mating pheromone a-factor. Cell 1986 ; 47: 413-422.
32. Elble R.: A simple and efficient procedure for transformation of yeasts. BioTechniques 1992 ; 13: 18-20.
33. Michaelis S., Herskowitz I.: The a-factor pheromone of Saccharomyces cerevisiae is essential for mating. Mol Cell Biol 1988 ; 8: 1309-1318.
34. Plummer LJ, Hildebrandt ER, Porter SB, Rogers VA, McCracken J., Schmidt WK: Mutational analysis of the ras converting enzyme reveals a requirement for glutamate and histidine residues. J Biol Chem 2006 ; 281: 4596-4605.
35. Heim R., Tsien RY: Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer. Curr Biol 1996 ; 6: 178-182.
36. Oldenburg KR, Vo KT, Michaelis S., Paddon C.: Recombination-mediated PCR-directed plasmid construction in vivo in yeast. Nucleic Acids Res 1997 ; 25: 451-452.
37. Porter S., Hildebrandt E., Breevoort S., Dore T., Schmidt W.: Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones. Biochim Biophys Acta 2007 ; 1773: 853-862.
38. Schmidt WK, Tam A., Michaelis S.: Reconstitution of the Ste24p-dependent N-terminal proteolytic step in yeast a-factor biogenesis. J Biol Chem 2000 ; 275: 6227-6233.
39. Marcus S., Caldwell GA, Miller D., Xue C-B., Naider F., Becker JM: Significance of C-terminal cysteine modifications to the biological activity of the Saccharomyces cerevisiae a-factor mating pheromone. Mol Cell Biol 1991 ; 11: 3603-3612.
40. Ma Y-T., Gilbert B., Rando R.: Inhibitors of the isoprenylated protein endoprotease. Biochemistry 1993 ; 32: 2386-2393.
41. McGovern SL, Helfand BT, Feng B., Shoichet BK: A specific mechanism of nonspecific inhibition. J Med Chem 2003 ; 46: 4265-4272.
42. Seidler J., McGovern SL, Doman TN, Shoichet BK: Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem 2003 ; 46: 4477-4486.
43. Coan KE, Shoichet BK: Stability and equilibria of promiscuous aggregates in high protein milieus. Mol Biosyst 2007 ; 3: 208-213.
44. Bergo MO, Ambroziak P., Gregory C., George A., Otto JC, Kim E.,, et al. Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol 2002 ; 22: 171-181.
45. Michaelson D., Ali W., Chiu VK, Bergo M., Silletti J., Wright L.,, et al. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell 2005 ; 16: 1606-1616.
46. Reddie KG, Roberts DR, Dore TM: Inhibition of kinesin motor proteins by adociasulfate-2. J Med Chem 2006 ; 49: 4857-4860.
47. Bulavin D., Belova G., Fornace AJ: Compounds and methods for inhibiting Wip1 phosphatase and treating cancer, and screening method. US Pat Appl Publ 2004: 15.
48. Perabo FG, Wirger A., Kamp S., Lindner H., Schmidt DH, Muller SC,, et al. Carboxyamido-triazole (CAI), a signal transduction inhibitor, induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2. Anticancer Res 2004 ; 24: 2869-2877.
49. Guo L., Li Z-S., Wang H-L., Ye C-Y., Zhang D-C.: Carboxyamidotriazole inhibits proliferation of human breast cancer cells via G2/M cell cycle arrest and apoptosis. Eur J Pharmacol 2006 ; 538: 15-22.
50. Bond A., Reichert Z., Stivers JT: Novel and specific inhibitors of a poxvirus type I topoisomerase. Mol Pharmacol 2006 ; 69: 547-557.